• Contact us
  • E-Submission
ABOUT
BROWSE ARTICLES
JOURNAL POLICIES
FOR CONTRIBUTORS

Page Path

41
results for

"Carcinoma"

Filter

Article category

Keywords

Publication year

Authors

"Carcinoma"

Review articles

[English]
Management strategies for advanced hepatocellular carcinoma with portal vein tumor thrombosis
Jeayeon Park, Su Jong Yu
Ewha Med J 2025;48(1):e4.   Published online January 31, 2025
DOI: https://doi.org/10.12771/emj.2025.e4

Hepatocellular carcinoma with portal vein tumor thrombosis presents a significant therapeutic challenge due to its poor prognosis and limited treatment options. This review thoroughly examines diagnostic methods, including imaging techniques and classification systems such as the Japanese Vp and Cheng’s classifications, to aid in clinical decision-making. Treatment strategies encompass liver resection and liver transplantation, particularly living donor liver transplantation after successful downstaging, which have shown potential benefits in selected cases. Locoregional therapies, including hepatic arterial infusion chemotherapy, transarterial chemoembolization, transarterial radioembolization, and external beam radiation therapy, remain vital components of treatment. Recent advancements in systemic therapies, such as sorafenib, lenvatinib, and immune checkpoint inhibitors (e.g., atezolizumab plus bevacizumab) have demonstrated improvements in overall survival and progression-free survival. These developments underscore the importance of a multidisciplinary and personalized approach to improve outcomes for patients with hepatocellular carcinoma and portal vein tumor thrombosis.

  • 9,603 View
  • 137 Download

Special topic: recent management strategies for liver cancer

[English]
Imaging findings of intrahepatic cholangiocarcinoma for prognosis prediction and treatment decision-making: a narrative review
Jun Gu Kang, Taek Chung, Dong Kyu Kim, Hyungjin Rhee
Ewha Med J 2024;47(4):e66.   Published online October 31, 2024
DOI: https://doi.org/10.12771/emj.2024.e66

Intrahepatic cholangiocarcinoma (iCCA) is a heterogeneous bile duct adenocarcinoma with a rising global incidence and a poor prognosis. This review aims to present a comprehensive overview of the most recent radiological research on iCCA, focusing on its histopathologic subclassification and the use of imaging findings to predict prognosis and inform treatment decisions. Histologically, iCCA is subclassified into small duct (SD-iCCA) and large duct (LD-iCCA) types. SD-iCCA typically arises in the peripheral small bile ducts and is often associated with chronic hepatitis or cirrhosis. It presents as a mass-forming lesion with a relatively favorable prognosis. LD-iCCA originates near the hepatic hilum, is linked to chronic bile duct diseases, and exhibits more aggressive behavior and poorer outcomes. Imaging is essential for differentiating these subtypes and assessing prognostic factors like tumor size, multiplicity, vascular invasion, lymph node metastasis, enhancement patterns, and intratumoral fibrosis. Imaging-based prognostic models have demonstrated predictive accuracy comparable to traditional pathological staging systems. Furthermore, imaging findings are instrumental in guiding treatment decisions, including those regarding surgical planning, lymphadenectomy, neoadjuvant therapy, and the selection of targeted therapies based on molecular profiling. Advancements in radiological research have improved our understanding of iCCA heterogeneity, facilitating prognosis prediction and treatment personalization. Imaging findings assist in subclassifying iCCA, predicting outcomes, and informing treatment decisions, thus optimizing patient management. Incorporating imaging-based approaches into clinical practice is crucial for advancing personalized medicine in the treatment of iCCA. However, further high-level evidence from international multicenter prospective studies is required to validate these findings and increase their clinical applicability.

  • 5,920 View
  • 77 Download
[English]

Metabolic dysfunction-associated steatohepatitis (MASH) is increasingly recognized as a leading cause of hepatocellular carcinoma (HCC), the third-leading cause of cancer mortality worldwide, driven by the global obesity epidemic. Projected to become the primary cause of HCC by 2030, MASH-HCC presents unique clinical challenges. This review examines its clinical management, including surveillance strategies and treatment advances, and discusses prospects to overcome existing challenges. MASH-HCC accounts for 10%–20% of HCC cases, particularly in Western countries, with a rising incidence due to obesity. Risk factors include cirrhosis, diabetes, obesity, alcohol, smoking, genetic polymorphisms (e.g., PNPLA3), and microbiome alterations. The pathogenesis involves fibrosis, immune dysfunction (e.g., T-cell impairment), and molecular changes. Prevention focuses on lifestyle modifications. Surveillance in patients with MASH cirrhosis is crucial but is hindered by poor ultrasound sensitivity in obese patients, necessitating alternative methods. Treatment mirrors that of other HCC types, but comorbidities and potentially reduced efficacy of immunotherapy necessitate tailored approaches. MASH is becoming the leading cause of HCC, necessitating lifestyle interventions for prevention. Improved surveillance and early detection are critical but challenging due to obesity-related factors. Treatments align with those for other HCC types, but comorbidities and potential differences in immunotherapy efficacy due to T-cell dysfunction require careful consideration. Key needs include identifying molecular drivers in non-cirrhotic metabolic dysfunction-associated steatotic liver disease, developing preventive therapies, refining surveillance methods, and tailoring treatments. Trials should specifically report MASH-HCC outcomes to enable personalized therapies. Further research is needed to understand T-cell dysfunction, optimize immunotherapies, and identify predictive biomarkers.

  • 4,398 View
  • 78 Download
  • 1 Web of Science
[English]
The histopathological and molecular heterogeneity of hepatocellular carcinoma: a narrative review
Wonju Chung, Haeryoung Kim
Ewha Med J 2024;47(4):e58.   Published online October 31, 2024
DOI: https://doi.org/10.12771/emj.2024.e58

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related deaths worldwide, with poor clinical outcomes due to challenges in early detection and limited efficacy of current treatments such as receptor tyrosine kinase inhibitors and immunotherapy. HCC exhibits significant heterogeneity at both histopathological and molecular levels, complicating its management but offering potential for personalized therapeutic approaches. This review outlines the morpho-molecular heterogeneity of HCC and summarizes various histological subtypes, including steatohepatitic, clear cell, macrotrabecular-massive, scirrhous, lymphocyte-rich, and fibrolamellar HCCs. Each subtype possesses distinct clinical, histological, and molecular features; for instance, steatohepatitic HCC is associated with metabolic dysfunction and shows IL-6/JAK/STAT activation, while clear cell HCCs often have IDH1 mutations and favorable prognosis. The macrotrabecular-massive subtype is linked to poor outcomes and TP53 mutations, whereas scirrhous HCCs express stemness markers and have TSC1/TSC2 mutations. Lymphocyte-rich HCCs are characterized by immune cell infiltration and better prognosis. CTNNB1-mutated HCCs show specific morphological features and may benefit from targeted therapies. Understanding these subtypes and associated molecular alterations is crucial for developing effective diagnostic and therapeutic strategies, including potential predictive biomarkers and personalized treatments. Additionally, the identification of patterns like vessels-encapsulating-tumor-clusters offers prognostic implications and may guide therapeutic decisions. Recent molecular studies have enhanced our comprehension of HCC heterogeneity, laying the groundwork for more personalized approaches. Pathologists play a vital role in recognizing these subtypes, aiding in prognosis prediction and treatment planning. Advances in digital pathology and artificial intelligence may further facilitate biomarker research, ultimately improving patient outcomes in HCC management.

Citations

Citations to this article as recorded by  
  • Gadoxetic acid-enhanced MRI in hepatocellular carcinoma: a comprehensive review of diagnostic, surveillance, and treatment response prediction and assessment
    Kumi Ozaki, Yukichi Tanahashi, Satoshi Goshima
    Japanese Journal of Radiology.2026; 44(1): 2.     CrossRef
  • Nanotechnology meets liver cancer: liposomal immunotherapy strategies for hepatocellular carcinoma
    Dev Kashyap, Manish Kumar, Ayush Singh, Arnav Kansal, Amanpreet Kaur, Shruti Srivastava, Vipin Saini, Jagpreet Kour
    Expert Review of Anticancer Therapy.2026; 26(1): 81.     CrossRef
  • Tackling data scarcity: Synthetic tumour and mask generation to improve image segmentation
    Félix Quinton, Benoit Presles, Romain Popoff, François Godard, Olivier Chevallier, Julie Pellegrinelli, Jean-Marc Vrigneaud, Jean-Louis Alberini, Fabrice Meriaudeau
    Artificial Intelligence in Medicine.2026; 173: 103348.     CrossRef
  • 4,023 View
  • 68 Download
  • 2 Web of Science
  • 3 Crossref
[English]
Current perspectives on the pharmacological treatment of advanced hepatocellular carcinoma: a narrative review
Hye-Jin Yoo, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
Ewha Med J 2024;47(4):e53.   Published online October 31, 2024
DOI: https://doi.org/10.12771/emj.2024.e53

Hepatocellular carcinoma (HCC) remains a critical health concern in Korea, ranking as the second leading cause of cancer mortality and imposing substantial economic burdens, particularly among the working-age population. This review examines recent advancements in treating advanced HCC, referencing the updated 2022 HCC guidelines and the Barcelona Clinical Liver Cancer system. Historically, first-line systemic therapies included sorafenib and lenvatinib, with regorafenib, cabozantinib, or ramucirumab serving as second-line options. Since 2020, immune checkpoint inhibitors have shown superior overall survival than sorafenib, leading to the adoption of combination therapies such as atezolizumab with bevacizumab and durvalumab with tremelimumab as first-line treatments. The IMbrave150 study demonstrated that atezolizumab–bevacizumab significantly extended median overall survival and progression-free survival, with the longest survival reported in any phase 3 trial for advanced HCC. Similarly, the HIMALAYA study indicated that durvalumab combined with tremelimumab significantly improved survival rates. Second-line therapies now include regorafenib, cabozantinib, ramucirumab, nivolumab with ipilimumab, and pembrolizumab, each offering benefits for specific patient populations. Nonetheless, these therapies are associated with side effects that require careful management. Traditional targeted therapies can lead to hypertension, cardiovascular events, and hand-foot skin reactions, whereas immune checkpoint inhibitors may cause immune-related adverse events affecting the skin, gastrointestinal tract, and endocrine system. Clinicians must be well-versed in these treatments and their potential side effects to provide optimal patient care. The emergence of combination therapies targeting complex biological pathways signifies a new paradigm in HCC treatment, emphasizing the importance of continuous education and vigilant monitoring to optimize patient outcomes.

Citations

Citations to this article as recorded by  
  • Novel Immunotherapy for Advanced Hepatocellular Carcinoma
    Hyun Bin Choi, Jeong-Ju Yoo
    The Korean Journal of Medicine.2025; 100(3): 102.     CrossRef
  • Immune checkpoint biology in hepatocellular carcinoma (Review)
    Ching-Hua Hsieh, Pei-Chin Chuang
    Oncology Letters.2025; 30(6): 1.     CrossRef
  • 6,793 View
  • 41 Download
  • 1 Web of Science
  • 2 Crossref

Case Report

Case Reports

[English]
Gastric adenocarcinoma with enteroblastic differentiation in a 67-year-old man in Korea: a case report
Hae Rin Lee, Gwang Ha Kim, Dong Chan Joo, Moon Won Lee, Bong Eun Lee, Kyung Bin Kim
Ewha Med J 2024;47(2):e28.   Published online April 30, 2024
DOI: https://doi.org/10.12771/emj.2024.e28

We report a rare case of gastric adenocarcinoma with enteroblastic differentiation (GAED) that was treated with endoscopic submucosal dissection followed by additional distal gastrectomy with lymph node dissection. A 67-year-old man underwent endoscopic submucosal dissection for a gastric lesion, which was diagnosed as GAED with submucosal and lymphatic invasion. Histologically, GAED is characterized by a tubulopapillary growth pattern and clear cells that resemble those of the primitive fetal gut. Immunohistochemically, GAED variably expresses oncofetal proteins such as glypican-3, alpha-fetoprotein, and spalt-like transcription factor 4. Despite negative margins, additional gastrectomy with lymph node dissection was performed due to submucosal and lymphatic invasion. No residual tumor or metastasis was detected, and the patient remained disease-free for 2 years before dying from causes unrelated to GAED. Given its aggressive nature, frequent lymphovascular invasion, and high metastatic potential, clinicians should recognize the histopathological diagnosis of this rare tumor and its propensity for aggressiveness.

  • 1,243 View
  • 20 Download

Review article

[English]
Sex differences in metabolic dysfunction-associated steatotic liver disease: a narrative review
Sae Kyung Joo, Won Kim
Ewha Med J 2024;47(2):e17.   Published online April 30, 2024
DOI: https://doi.org/10.12771/emj.2024.e17

Understanding the effects of sex and sex differences on liver health and disease is crucial for individualized healthcare and informed decision-making for patients with liver disease. The impact of sex on liver disease varies according to its etiology. Women have a lower prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) than men. However, postmenopausal women face a higher risk of advanced liver fibrosis due to hormonal influences. Sex differences affect the pathogenesis of MASLD, which involves a complex process involving several factors such as hormones, obesity, and the gut microbiome. Furthermore, sex-related differences in the development of MASLDrelated hepatocellular carcinoma have been observed. The sex-specific characteristics of MASLD necessitate an individualized management approach based on scientific evidence. However, research in this area has been lacking. This article reviews the current understanding of sex differences in MASLD.

Citations

Citations to this article as recorded by  
  • Unveiling the Burden of Steatotic Liver Disease: Mortality Risks by Subtype and Fibrosis Stage in a Nationwide Cohort
    Qi Feng, Pinelopi Manousou, Chioma N. Izzi‐Engbeaya, Rohit Loomba, Mark Thursz, Mark Woodward
    Liver International.2026;[Epub]     CrossRef
  • KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025
    Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang
    Clinical and Molecular Hepatology.2025; 31(Suppl): S1.     CrossRef
  • MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women
    Ilaria Milani, Marianna Chinucci, Frida Leonetti, Danila Capoccia
    Biomedicines.2025; 13(4): 855.     CrossRef
  • Sex and gender disparities in hepatocellular carcinoma: insights into risk, diagnosis, and therapeutic outcomes
    Tu Tuan Tran, Huy The Be, Khanh Dinh Hoang, Hoang Duc Dong
    Clinical and Translational Oncology.2025; 27(12): 4301.     CrossRef
  • Curcumin for Inflammation Control in Individuals with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial
    Metha Yaikwawong, Laddawan Jansarikit, Siwanon Jirawatnotai, Somlak Chuengsamarn
    Nutrients.2025; 17(12): 1972.     CrossRef
  • Mediation analysis of the molecular phenotypes in a severe MASH-like liver injury mouse model
    Zhuolin Song, Volodymyr P Tryndyak, Rose A Willett, Igor P Pogribny, Ivan Rusyn, Fred A Wright
    Toxicological Sciences.2025; 208(1): 155.     CrossRef
  • Association between dairy consumption and metabolic dysfunction-associated steatotic liver disease among Korean adults: Evidence from the prospective health examinees cohort
    Wuttyi Khaing, Uyangamaa Nyamsuren, Sangah Shin
    Nutrition Research.2025; 144: 38.     CrossRef
  • Association Between Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and Short-Term Progression of Carotid Atherosclerosis Among Early Middle Age Adults
    Wenjing Xiao, Xinghe Sun, Hui Lv, Xiaohui Liu, Jihong Zhu
    Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 4535.     CrossRef
  • The Prevalence of Liver Enzyme Abnormalities Among Adult Patients with Non-Communicable Diseases in Rwanda: A Gender-Stratified Analysis
    Noa Tuyikurikire, Emmanuel Tuyizere, Janvier Imanishimwe, Aime Ahishakiye, Happy Jean Bosco Asifiwe, Emmanuel Rubayiza, James Gafirita, Herbert Mapira, Augustin Nzitakera, Araya Wasihun, Cuthbert Musarurwa
    Hepatic Medicine: Evidence and Research.2025; Volume 17: 199.     CrossRef
  • Implication of the Androgen Receptor in Muscle–Liver Crosstalk: An Overlooked Mechanistic Link in Lean-MASLD
    Eleni Myrto Trifylli, Christiana Charalambous, Nikolaos Spiliotopoulos, Nikolaos Papadopoulos, Anastasia Oikonomou, Spilios Manolakopoulos, Melanie Deutsch
    Livers.2025; 5(4): 65.     CrossRef
  • Associations between steatotic liver disease subtypes and incident diabetes in young Korean adults: A nationwide cohort study
    Goh Eun Chung, Su Jong Yu, Jeayeon Park, Yoon Jun Kim, Jung‐Hwan Yoon, Kyungdo Han, Eun Ju Cho
    Diabetes, Obesity and Metabolism.2025;[Epub]     CrossRef
  • Sex and gender differences in MASLD: pathophysiological mechanisms, clinical implications, and future directions
    Mohamad Jamalinia, Samira Saeian, Nima Nikkhoo, Amirhossein Nazerian, Kamran Bagheri Lankarani
    Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
  • High-Sensitivity C-Reactive Protein Levels in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Alcohol-Associated Liver Disease (MetALD), and Alcoholic Liver Disease (ALD) with Metabolic Dysfunction
    Seong-Uk Baek, Jin-Ha Yoon
    Biomolecules.2024; 14(11): 1468.     CrossRef
  • 4,182 View
  • 52 Download
  • 5 Web of Science
  • 13 Crossref

Original Article

[English]
Clinical Characteristics, Treatment Delivery, and Cisplatin Eligibility in Korean Patients Initially Diagnosed with Urothelial Carcinoma
Kwonoh Park, Jong Kil Nam, Bon Jin Koo, Hyun Jung Lee, Tae Un Kim, Hwaseong Ryu, Yun Jeong Hong, Seungsoo Lee, Dong Hoon Lee, Sung Woo Park
Ewha Med J 2021;44(3):63-69.   Published online July 31, 2021
DOI: https://doi.org/10.12771/emj.2021.44.3.63
Objectives

The aim of this study was to examine the clinical presentation, treatment delivery, and cisplatin eligibility of Korean patients with urothelial carcinoma (UC) in a real-world setting.

Methods

We performed a retrospective cohort study of patients initially diagnosed with UC from March 2013 to June 2018. Creatinine clearance >60 mL/min and Eastern Cooperative Oncology Group performance status (0-1) were adopted as cisplatin eligibility criteria.

Results

This study included 557 eligible patients. Median age was 71.0 years (range, 33-94 years), and males were dominant (80%). Primary tumor sites were: upper genitourinary tract, 18%; bladder, 81%; and urethra, 0.4%. Initial disease status was non-muscle invasive bladder cancer (313, 56%), diffuse infiltrating non-muscle invasive bladder cancer (19, 3%), cTanyN0 upper tract UC (75, 13%), cT2-4N0 bladder UC (82, 15%), TanyN1-3 UC (36, 7%), or initially metastatic UC (32, 6%). At the time of analysis (June 2019), following treatments were delivered to 134 patients with localized UC: radical operation with or without perioperative treatment (89, 67%), definitive chemoradiation (7, 5%), and palliative surgery or supportive care only (36, 28%). In total, 89 patients had metastatic UC, including those with recurrent disease (n=57), and 34 (38%) of the 89 were eligible for cisplatin.

Conclusion

Clinical presentations in East Asian UC patients were consistent with those of previous studies in other countries, except for a relatively high incidence of upper genitourinary tract. Our results can serve as a benchmark for further advances and future research for treatments of UC in East Asian patients.

Citations

Citations to this article as recorded by  
  • Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis
    Mairead Kearney, Liu Zhang, Elizabeth Hubscher, Mihaela Musat, Sharada Harricharan, Thomas Wilke
    Future Oncology.2024; 20(16): 1123.     CrossRef
  • Four versus six cycles of platinum-based chemotherapy for advanced Urothelial carcinoma in the era of immune checkpoint inhibitors: A retrospective cohort study (FOCUS, KCSG-GU23-08)
    Kwonoh Park, Eo Jin Kim, Jin Young Kim, Hyojeong Kim, Inkeun Park, Joo-Hwan Park, Byeong Seok Sohn, Hyo Jin Lee, Jungmin Jo, Seok Jae Huh, Jae Lyun Lee
    Current Problems in Cancer.2024; 53: 101149.     CrossRef
  • Phase II study of neoadjuvant chemotherapy with four cycles of dose‐dense MVAC followed by radical cystectomy in Korean patients with muscle‐invasive or locally advanced urothelial carcinoma of bladder
    Kwonoh Park, Hyun Jung Lee, Tae Un Kim, Hwaseong Ryu, Yong Kan Ki, Yun Jeong Hong, Jong Kil Nam
    Asia-Pacific Journal of Clinical Oncology.2023; 19(6): 739.     CrossRef
  • 1,295 View
  • 13 Download
  • 3 Web of Science
  • 3 Crossref

Case Report

[English]
Clear Cell Adenocarcinoma Originated from Adenomyosis
Sunwha Park, Angela Cho, Chul Min Park
Ewha Med J 2019;42(1):10-13.   Published online January 29, 2019
DOI: https://doi.org/10.12771/emj.2019.42.1.10

A 66-year-old postmenopausal woman received routine gynecologic check-up. Transvaginal ultrasonography and abdominal and pelvic computed tomography showed about 5-cm cystic mass in uterus with solid component and the patient had thin endometrium and the serum level of CA 125 was normal. We performed a total hysterectomy and bilateral salpingo-oophorectomy and found tumor which had brownish cystic fluid and about 2 cm sized and colored in light yellowish, polypoid protruding solid mass, located within the myometrial wall. Histopathological examination of frozen section revealed malignancy. The tumor was confined within the myometrium and its histologic type was clear cell adenocarcinoma. Finally we identified that the myometrial mass was clear cell adenocarcinoma originated from adenomyosis pathologically. The malignant transformation of adenomyosis is very rare. When we find a cystic change with solid component in adenomyosis patients, clear cell adenocarcinoma should be suspected as a differential diagnosis and magnetic resonance imaging should be considered for further evaluation.

  • 542 View
  • 3 Download

Original Article

[English]
Invasive Lobular Carcinoma: Detection and Multiplicity with Multimodalities
In Hye Chae, Eun-Suk Cha, Jee Eun Lee, Jeoung Hyun Kim, Bom Sahn Kim, Jin Chung
Ewha Med J 2018;41(2):27-34.   Published online April 30, 2018
DOI: https://doi.org/10.12771/emj.2018.41.2.27
Objectives

We aimed to compare the diagnostic performances of digital mammography (DM), digital breast tomosynthesis (DBT), ultrasound (US), magnetic resonance imaging (MRI), breast specific gamma imaging (BSGI) and/or positron emission tomography/computed tomography (PET/CT) for the detection of invasive lobular carcinoma (ILC).

Methods

Index ILCs and multifocal/multicentric (multiple) ILCs were analyzed using various imaging modalities. The final surgical pathology was regarded as the reference standard. The detection rate for index cancers and the diagnostic performance for multiple ILCs per breast were evaluated.

Results

Seventy-eight ILCs in 76 women were enrolled. Twenty-six breasts had multiple ILCs. DM (n=72), DBT (n=15), US (n=77), MRI (n=76), BSGI (n=50), and /or PET/CT (n=74) were performed. For index cancer, the detection rate was 100% for DBT, US, and MRI. For multiple ILCs, the sensitivity was 100% for DBT and MRI (P<0.001). The diagnostic accuracy for multiple ILCs were 73.3% for DBT and 73.0% for PET/CT (P=0.460).

Conclusion

DBT was the most accurate imaging modality for both index and multiple ILCs. PET/CT was also valuable for multiple ILCs, whereas DM and BSGI showed relatively low diagnostic performances. DBT and PET/CT have promising roles in the diagnosis of multiple ILCs.

Citations

Citations to this article as recorded by  
  • Contrast-Enhanced Mammography for Detection and Characterization of Invasive Lobular Carcinoma
    Maria Gosein, Charlotte J. Yong-Hing, Priya Johal, Colin Mar, Tetyana Martin
    Canadian Association of Radiologists Journal.2025;[Epub]     CrossRef
  • A comparative study between the diagnostic performance of contrast-enhanced digital mammography and dynamic contrast-enhanced MRI in invasive lobular carcinoma of the breast
    Sherihan Fakhry, Rasha Mohamed Kamal, Omnia Mokhtar Nada, Amira Emad Abo El Enien Mohamed, Mennatallah Mohamed Hanafy
    Egyptian Journal of Radiology and Nuclear Medicine.2024;[Epub]     CrossRef
  • Breast-specific gamma imaging versus ultrasound and mammography for breast cancer diagnosis: A meta-analysis
    Y. Zhang, D. Zhu, R. Feng
    International Journal of Radiation Research.2024; 22(1): 27.     CrossRef
  • 998 View
  • 4 Download
  • 3 Crossref

Case Reports

[English]
Unilateral Ptosis with Bilateral Incomplete Ophthalmoplegia as the Initial Presentation in Metastatic Cancer
Ji-Hyun Choi, Hyung Jun Park, Kyoung-Gyu Choi, Key Hwan Lim, Kee Duk Park
Ewha Med J 2017;40(3):136-139.   Published online July 28, 2017
DOI: https://doi.org/10.12771/emj.2017.40.3.136

Orbital metastases are rare and predominantly unilateral occurrences. Bilateral metastases affecting the extraocular muscles are extremely rare. A few case reports of bilateral metastases to extraocular muscles described binocular diplopia with conspicuous bilateral external ophthalmoplegia as an initial symptom. We report a case in which unilateral ptosis was an initial symptom and bilateral incomplete ophthalmoplegia was found on initial neurologic examination in invasive ductal carcinoma of the breast. The patient had hormone receptor-positive breast cancer, and so was treated by hormonal therapies and closely monitored. The presence of a secondary orbital lesion presents many difficulties of differential diagnosis and treatment. A thorough neurologic examination to detect ocular manifestations is most important for localization and broad differential diagnosis including mechanical orbital metastatic lesion.

Citations

Citations to this article as recorded by  
  • Extraocular muscle enlargement
    Khizar Rana, Valerie Juniat, Sandy Patel, Dinesh Selva
    Graefe's Archive for Clinical and Experimental Ophthalmology.2022; 260(11): 3419.     CrossRef
  • 791 View
  • 0 Download
  • 1 Crossref
[English]
Early Detection of Hidden Adenocarcinoma through the Prompt Pericardiocentesis in Patient with Small Pericardial Effusion
Batzaya Shinebayar, Se Yong Gill, Haemin Jeong, Kyung-Chan Choi, Junshik Hong, Sang Min Park
Ewha Med J 2017;40(2):91-93.   Published online April 28, 2017
DOI: https://doi.org/10.12771/emj.2017.40.2.91

Pericardial drainage is an important diagnostic and therapeutic option in the symptomatic patient with large amount of pericardial effusion (PE). However, when the amount of PE is relatively small, physicians are often reluctant to perform the invasive drainage of the fluid due to the increased risk of causing myocardial injury during the procedure. Even in some cases of suspected pericarditis with small amount PE, an initial empirical anti-inflammatory therapy is often recommended. A 65-year-old woman presented with mild dyspnea for two weeks. The echocardiography revealed small amount of PE. A careful fluoroscopy-guided pericardiocentesis, subsequent pericardial fluid cytology, and thorough whole body check-up demonstrated adenocarcinoma with no proven primary site. After the palliative chemotherapy, she had survived for 15 months until her death due to asphyxia. Although pericardiocentesis is considered dangerous in small amount of PE, a prompt and careful drainage may provide early detection of hidden malignancy and better survival outcome.

  • 419 View
  • 0 Download

Original Article

[English]
MRI Findings of Lipiodol Uptake in Hepatocellular Carcinomas: A Focus on Signal Intensity
Myung Jae Lee, Min Jeong Kim, Seung Yon Baek
Ewha Med J 2016;39(4):110-117.   Published online October 27, 2016
DOI: https://doi.org/10.12771/emj.2016.39.4.110
Objectives

To evaluate MRI findings of non-recurrent hepatocellular carcinomas with lipiodol uptake (LHCCs) treated with transarterial chemoembolization.

Methods

28 LHCCs were divided into two groups according to amount of lipiodol uptake and tumor size, retrospectively. According to amount of lipiodol uptake, HCCs were classified into group A with dense lipiodol uptake (more than 90%) and group B with partial lipiodol uptake (between 50% and 90%). For HCC size analysis, group I was defined by a longest diameter of less than 2 cm, and group II was defined by a longest diameter of greater than or equal to 2 cm.

Results

In group A (n=16), eight LHCCs showed high signal intensity (SI) on T2-weighted images (T2WI), ten LHCCs showed low SI on T1-weighted imaged (T1WI), six LHCCs showed decreased SI at higher b value of diffusion-weighted images (DWI). In group B (n=12), six LHCCs revealed high SI on T2WI, six LHCCs revealed low SI on T1WI, ten LHCCs decreased SI at higher b value of DWI. As compared with tumor size and SI, six of 12 LHCCs in group I and eight of 16 LHCCs in group II showed high SI on T2WI. Six LHCCs in group I and ten LHCCs in group II showed low SI on T1WI. All LHCCs were not enhanced.

Conclusion

Signal intensities of LHCCs were variable, but more than half of LHCCs showed high SI on T2WI, low SI on T1WI, decreased SI at higher b value of DWI, regardless of lipiodol uptake or tumor size.

Citations

Citations to this article as recorded by  
  • Comparison of contrast-enhanced ultrasonography and MRI results obtained by expert and novice radiologists indicating short-term response after transarterial chemoembolisation for hepatocellular carcinoma
    C.-C. Lee, J.-I. Hwang, K.-H. Chang, Y.C. Lin, C.C. Chao, T.-F. Cheng, Y.-C. Chen, K.-C. Hsueh
    Clinical Radiology.2024; 79(1): e73.     CrossRef
  • 867 View
  • 3 Download
  • 1 Crossref

Case Reports

[English]
Living Donor Liver Transplantation in a Hepatitis B Patient with Acute on Chronic Liver Failure Accompanying Hepatocellular Carcinoma
Hee Jin Hong, Joo Ho Lee, Yun Bin Lee, Hana Park, Seong Gyu Hwang, Kyu Sung Rim
Ewha Med J 2016;39(3):76-80.   Published online July 29, 2016
DOI: https://doi.org/10.12771/emj.2016.39.3.76

Acute clinical deterioration in patients with chronic liver disease is called acute on chronic liver failure (ACLF). Principles of management of ACLF consist of early identifying etiology of liver disease, rapid intervention of precipitating event and discreet intensive cares. Despite medical intensive cares, if liver failure progresses, liver transplantation could be the other option. Also, liver transplantation is the only treatment that offers a chance of cure for hepatocellular carcinoma (HCC) and the underlying liver cirrhosis simultaneously. Emergent living donor liver transplantation (LDLT) can be performed for patients with acute liver failure and improves survival rate, especially in circumstances which liver graft is often not available because of deceased donors are not affordable. Here, we describe a chronic hepatitis B patient who developed ACLF accompanying early HCC. Because he did not improved with medical care, he received emergent LDLT. After LDLT, he showed great improvement without critical complications.

Citations

Citations to this article as recorded by  
  • Systematic review with meta‐analysis: liver transplant provides survival benefit in patients with acute on chronic liver failure
    Mohamed A. Abdallah, Muhammad Waleed, Matthew G. Bell, Morgan Nelson, Robert Wong, Vinay Sundaram, Ashwani K. Singal
    Alimentary Pharmacology & Therapeutics.2020; 52(2): 222.     CrossRef
  • 615 View
  • 0 Download
  • 1 Crossref
[English]
Metastatic Pulmonary Mucoepidermoid Carcinoma with Fulminant Clinical Course
Yong Won Park, Seon Bin Yoon, Mi Ju Cheon, Young Min Koh, Hyeon Sik Oh, Se Joong Kim, Seung Hyeun Lee
Ewha Med J 2015;38(2):85-89.   Published online July 29, 2015
DOI: https://doi.org/10.12771/emj.2015.38.2.85

Pulmonary mucoepidermoid carcinoma (MEC) is a rare form of lung cancer that originates from submucosal glands of tracheobronchial tree. Unlike low-grade tumor with benign nature, high-grade case is even rarer and has aggressive clinical features with no definite treatment option. Here, we report a case of high-grade pulmonary MEC with fulminant clinical course. A 74-year-old man presented with cough, sputum and mental change. Chest imaging showed massive mediastinal lymphadenopathy with obstructive pneumonia, and multiple metastases in lung and adrenal gland. Bronchoscopy showed polypoid masses obstructing right main bronchus and bronchus intermedius. Histopathology revealed a mixture of glandular structure lined with mucussecreting cells and nests of squamoid cells with nuclear atypia and pleomorphism, which is compatible with high-grade MEC. We intensively treated the patient with combination antibiotics and ventilator care. However, the patient did not respond to the treatment and rapidly deteriorated, and finally expired a month after diagnosis.

  • 440 View
  • 0 Download

Original Articles

[English]
Expression of Tumor Necrosis Factor-Alpha and Interleukin-6 in Larynx Squamous Cell Carcinoma
Sung Min Chung, Sung Sook Kim
Ihwa Ŭidae chi 1996;19(3):349-357.   Published online July 24, 2015
DOI: https://doi.org/10.12771/emj.1996.19.3.349
Background

The host immune system normally functions to destroy neoplastic cells that continually develop as a result of somatic mutations. However, patients with head and neck squamous cell carcinoma have depressed cell-mediated immune function, which has recently been shown to be most pronounced in the local and regional environment of the primary tumor. Recent studies suggest a local modulation of the host immune response to tumor by secreted immunoregulatory factors such as cytokines, especially pro-inflammatory cytokines(interleukin-1, interleukin-6, interleukin-8, interferons, and tumor necrosis factor).

Materials and Methods

To assessthe ability of head and neck squamous cell carcinoma to produce these cytokines, initially, we have performed immunohistochemical staing for interleukin-6 and tumor necrosis factor in 20 cases of laryngeal squamous cell carcinoma and 10 cases of laryngeal nodule as a control group.

Results

We detected interleukin-6 in 11 cases of laryngeal squamous cell carcinoma(55%) and tumor necrosis factor in 11 cases of laryngeal squamous cell carcinoma(55%). All of 10 papillomas showed no expression of interleukin-6 and tumor necrosis factor. There is no statistical correlation between interleukin-6 and tumor necrosis factor expression and clinical stage or pathologic grade.

Conclusion

These results suggest that laryngeal squamous cell carcinoma may secrete cytokines influencing the response of local immune cells. But future studies of the role of tumorderived cytokines in the local immune response to tumor could be investigated,since cytokines may directly or indirectly regulate tumor growth and metastasis.

  • 338 View
  • 0 Download
[English]
Objectives

To compare fast spin echo(FSE) T2WI of the body coil(BC) with FSE T2WI of the endorectal surface coil(ERC) in the evaluation of parametrial and vaginal invasion and to evaluate tue dynamic enhanced images on the aspect of parametrial invasion.

Materials and methods

Twenty consecutive patients of uterine cervical carcinomas confirmed by biopsy were included in this study and staging was determined by the surgery (2 cases) and the radiologic and clinical studies(18 cases). 1.5T Signa(GE,USA) was used and FSE T2-weighted axial and sagittal images were obtained by the body coil and endorectal surface coil respectively. Then dynamic enhanced axial images with FMPSPGR were performed at 2-3 slices of cervical cancer level. Parametrial and vaginal invasion on the body coil images were compared with those on the endorectal coil images retrospectively. Parametrial enhancement was evaluated on the dynamic enhanced images.

Results

The accuracy of parametrial invasion was 100% of BC and 60% of ERC in 5 cases below stage Ib, 64% of BC and 73% of ERG in 11 cases of stage IIb and IIIa, 100% of BC and ERC in 4 cases above stage IVa. Overall accuracy of parametrial invasion was 80% of Bc and 75% of ERC without significant difference between two images. The accuracy of vagianl invasion was 80% of BC and 100% of ERC below stage Ib, 100% of BC and ERC above stage IIb. Overall accuracy of vaginal invasion was 95% of BC and 100% of ERC without difference between two images. On the dynamic enhanced images, parametrial enhancement was seen in all 20 cases and vascular enhancement in the parametrium was noted in 9 pf 20(45%) cases regardless of parametrial invasion.

Conclusion

There was no difference between BC and ERC images to evaluate the accuracy of parametrial and vaginal invasion. Therefore, ERC should be used in the cases which revealed suspicious invasion on BC images. Dynamic-enhanced images were not useful in the evaluation of parametrial invasion.

  • 286 View
  • 0 Download
[English]
Expression of Multidrug Resistance Gene Product in Laryngeal Squamous Cell Carcinoma
Sung Min Chung
Ihwa Ŭidae chi 1996;19(1):125-131.   Published online July 24, 2015
DOI: https://doi.org/10.12771/emj.1996.19.1.125
Objectives

Various mechanisms are involved in drug resistance of tumor cells. Among them one such mechanism is the overexpression of the multidrug resistance(mdr1) gene product P-glycoprotein(Pgp) that functions as an energy - dependent drug efflux pump.

Method

The expression of P-glycoprotein by immunohistochemistry was examined in 20 cases of laryngeal squamous cell carcinoma and vocal nodules as a control pump using a newly developed monoclonal antibody(MDR/JSB-1) which is specipic to human mdr1 gene product and recognizes an external epitope of the protein. Mdr1 gene product expression was compared with clinical response to chemotherapy in six patients who received mdr1 dependent drugs.

Result

The results are summerized as follows.

1) Among 20 laryngeal cancer tissues, P-glycoprotein was detected in 8 patients and none of 20 vocal nodules showed expression of P-glycoprotein.

2) There is a correlation in between positive P-glycoprotein staining and tumor differentiation.

3) No correlation in between positive P-glycoprotein standing and tumor stage of tumor site is observed.

4) 2 patients with negative clinical response to chemotherapy among 6 patients who received inductive chemotherapy with cisplatin, vincristine and p pepleomycin revealed positive P-glycoprotein staining.

Conclusion

Therefore, analyzing the expression of P-glycoprotein may play a role when planning chemotherapeutic regimens for patients with head and neck cancer and may be an additional prognostic and diagnostic tools in these patients.

  • 323 View
  • 0 Download

Case Reports

[English]
Wedge Resection of Lung Metastasis after Chemotherapy in Patients with Testicular Choriocarcinoma
Jee Young Oh, Soon Nam Lee, Young Yo Park, Kwang Ho Kim, Woon Sup Han
Ihwa Ŭidae chi 1995;18(3):269-275.   Published online July 24, 2015
DOI: https://doi.org/10.12771/emj.1995.18.3.269

Choriocarcinonla is very rare malignancy, accounting for less than 1% of all testicular germcell tumor. However, it is an important disease in the field of oncology, as it represents ahighly curable malignancy. and one in which the incidence is focused on young patients attheir peak of productivity. In nonserninomatous germ cell testis tumor, assessment of prognosticfactors is related to develop a basis for more rational therapy for each individual patient.Along with prognostic staging, appropriate treatment shoud be applied to each patient to improve disease-free survival. And. surgical resection of residual masses after cisplatin-based chemotherapy is an established adjuvant to chemotherapy, because complete remission can be improvedabout 10% with appropriately timed complete resection of residual diseases. So, we reporta case of a 27-year old male patient with testicular choriocarcinoma who presented with multiplelung metastases after radical orchiectomy. He recieved lung wedge resection after 8 cycles ofcisplatin, etoposide, ifosfamide combination chemotherapy. and complete remission was confirmed and maintained.

  • 367 View
  • 0 Download
[English]
A Case of Surgical Resection of Pulmonary Metastases in Patient with Resected Primary Colom Carcinoma
Jee Young Oh, Seung Ki Ryu, Seung Jung Kim, Jun-Hyuk Choi, Soon Nam Lee, Kwang Ho Kim, Woo Sup Han
Ihwa Ŭidae chi 1995;18(2):137-141.   Published online July 24, 2015
DOI: https://doi.org/10.12771/emj.1995.18.2.137

Although the role of surgical management of metastatic disease from primary carcinoma of the coln and recutm is still controversial, resection of hepatic metastasis improves survival rate of patients with primary colorectal carcinoma treated locally. The lung is the most common site of extra-abdominal metastasis following resection of a prymary colorectal tumor and not amenable to curative therapy.

It is possible to resect the pulmonary metastasis in selected patients following resection of colorectal cancers, but the 5-year survival rates are ranged from 9% to 57%. Authors report a case of resection of pulmonary metastasis occured 3 years after resection of primary colon carcinoma.

  • 327 View
  • 0 Download

Original Article

[English]

Estrogen receptor-related protein was examined on gastrectomy specime from 16 cases of advaced gastric adenocarcinoma and 7 cases of early gastric carcinoma(EGC) by using peroxidase-anti-peroxidase method on formalin-fixed paraffin-embedded sections. Positive reaction was seen in 7 out of 16 cases of advanced carcinoma and in 4 out of 8 cases of EGC(50%). Among advanced carcinoma, 3 cases of mucinous carcinoma were negative and 2 cases of signet ring cell carcinoma(SRC) showed focal positive reaction only in combined poorly differentiated(PD) area(10% of tumor cells). PD advanced carcinoma consisted of 4 cases of medullary type and 3 cases of individual cell type. Two out of 4 medullary type showed positive reaction in 20 and 80% of tumor cells and 2 out of 3 individual cell type showed positive reaction in 50 and 70% of tumor cells. Gland-forming type of advanced carcinoma consisted of 1 each case of intestinal and cardiac type and 1 mixed intestinal and cardiac type. Only 1 case of intestinal type showed positive reaction in 50% of tumor cells Among EGC, 2 cases of SRC were negative and 2 cases of PD carcinoma showed 5 and 10% positivity in PD area and 20 and 40% positivity in admixed gland-forming area. Gland-forming EGC consisted of 3 cased of intestinal type and 1 case of cardiac type. One case from each group showed positive reaction in 50 and 20% of tumor cells, respectively. In summary, positive reaction to antibody to estrogen receptor-related protein(P29) was expressed in PD(66.7%), gland-forming(50%), SRC, and mucinous type in order in both early and advanced carcinoma. The difference between age, sex, and other factors was not clear due to limitation of specimen.

  • 352 View
  • 0 Download

Case Reports

[English]
Surgical Treatment for Metastatic Hepatocarcinoma of the Spine: Two Cases
Ki Hong Choi, Chung Nam Kang, Jin Man Wang, Kwon Jae Roh, Chul Shin Kim
Ihwa Ŭidae chi 1989;12(2):147-154.   Published online July 24, 2015
DOI: https://doi.org/10.12771/emj.1989.12.2.147

Metastatic tumors of the spine often cause severe pain and paralysis because of deformity and neural encroachment. As oncology now extends the life expectancies of these patients, spinal decompression and stabilization are necessary.

2 patients who had vertebral metastases of hepatocarcinoma were operated on by decompressive corporectomy and firm stabilization. They had significant neural recovery and pain relief immediately.

Now, 2 cases are presented with a brief review of literatures.

  • 231 View
  • 0 Download
[English]
A Case of Squamous Cell Carcinoma Arising from Leukoplakia
Hae Young Choi, Jeong Hee Hahm, Hong Il Kook
Ihwa Ŭidae chi 1987;10(4):279-282.   Published online July 24, 2015
DOI: https://doi.org/10.12771/emj.1987.10.4.279

We present herein a case of squamous cell carcinoma arising from leukoplakia developed in 1 51-year-old male. He has had a walnut sized whitish plaque with a central ulceration for one year. Histopathologic findings grade II of squamous cell carcinoma. Ten months after irradiation, he died.

  • 312 View
  • 1 Download
[English]
Chemotherapy in Small Cell Lung Cancer with End-Stage Renal Disease on Hemodialysis
Sang Il Choi, Sun Seob Park, Eun Jeong Ko, Si Won Lee, Mihong Choi, Kiwon Kim
Ewha Med J 2014;37(Suppl):S5-S9.   Published online December 24, 2014
DOI: https://doi.org/10.12771/emj.2014.37.S.S5

Small cell lung cancer is primarily treated with chemotherapy. For patients with end-stage renal disease (ESRD), systemic chemotherapy is often challenging since renal excretion of chemotherapeutic agents might be decreased due to impaired renal function, leading to increased toxicity. No consensus is made so far regarding appropriate dosage and combination of chemotherapeutic agents for patients on hemodialysis. We report two cases of chemotherapy without significant toxicity in small cell lung cancer patients who were on hemodialysis for ESRD.

  • 635 View
  • 0 Download
[English]
Hepatocellular Carcinoma Arising from Non-Cirrhotic Non-Alcoholic Steatohepatitis
Min Roh, Tae Yeob Kim, Joo Hyun Sohn, Jae Keun Park, Seung Lee, Han Joon Kim, JuYeon Pyo, Young-Ha Oh
Ewha Med J 2014;37(Suppl):S33-S36.   Published online December 24, 2014
DOI: https://doi.org/10.12771/emj.2014.37.S.S33

The major risk factors of hepatocellular carcinoma include hepatitis B or C virus infection and alcohol consumption in Korea which lead to liver cirrhosis development and progression. However, prevalence of non-alcoholic fatty liver disease related hepatocellular carcinoma is rising worldwide and hepatocellular carcinoma cases in patients with non-cirrhotic non-alcoholic steatohepatitis are increasing. A hypoechoic nodule was incidentally detected in a 52-year-old woman, with no evidence of liver cirrhosis or specific hepatocellular carcinoma findings on radiological examination. Non-cirrhotic non-alcoholic steatohepatitis-associated hepatocellular carcinoma was diagnosed based on clinical, laboratory, and histopathological findings of liver biopsy. To our knowledge, this is the first such case report in Korea.

  • 504 View
  • 0 Download
[English]
A Favorable Treatment Response of Erlotinib in Lung Adenocarcinoma with Concomitant Activating EGFR Mutation and ROS1 Rearrangement
Min Hwan Kim, Yehyun Park, Hye Jung Park, Ah-young Ji, Changho Song, Moo-Nyun Jin, Young Ju Kim, Sun Wook Kim, Jung-Hee Lee, In-Soo Kim, Hye Ryun Kim, Joohang Kim, Byoung Chul Cho
Ewha Med J 2014;37(1):46-51.   Published online March 25, 2014
DOI: https://doi.org/10.12771/emj.2014.37.1.46

The rearrangement of c-ros oncogene 1 (ROS1) has been recently identified as an important molecular target in non small cell lung cancer (NSCLC). ROS1 rearrangement and epidermal growth factor receptor (EGFR) mutation were mutually exclusive each other in previous studies, and the clinical implication of co-existence of the two genetic alterations has not been determined. We report a case of 46-year-old female never-smoker NSCLC patient whose tumor harbored ROS1 rearrangement and EGFR mutation concomitantly. She had undergone curative surgery for stage IIIA NSCLC, and the recurrence in left pleura and brain occurred at 2 years after the surgery. She received several lines of chemotherapy including docetaxel plus carboplatin, erlotinib, pemetrexed, and gemcitabine. Erlotinib therapy showed a favorable treatment response with progression-free survival of 9.5 months and partial response of tumor on radiologic evaluations. This case represents a successful erlotinib treatment in a NSCLC patient with concurrent ROS1 rearrangement and EGFR mutation.

  • 357 View
  • 0 Download

Review Article

[English]
Renal Cell Neoplasms: Recent Advances
Sanghui Park, Jae Y. Ro
Ewha Med J 2014;37(1):16-25.   Published online March 25, 2014
DOI: https://doi.org/10.12771/emj.2014.37.1.16

The incidence of renal cell neoplasms has been increased in worldwide as well as in Korea. Even though the World Health Organization (WHO) Classification of renal tumors (2004) is currently used, new entities require to be added in the updated classification because of recent modification with our understanding of the molecular biology and different clinical behavior of new renal tumors. In this review, recently described tumors and candidate entities will be discussed. It is of importance to know these new entities for the proper diagnosis, treatment, and their prognosis.

  • 463 View
  • 0 Download

Case Reports

[English]
Acute Respiratory Distress Syndrome after Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: A Case Report
Yun Won Jo, Jeong-Mi Lee, Ja Yoon Choi, Dong-Hoon Lew, Ra Ri Cha, Hye Won Oh, Hong-Jun Kim, Hyun Ju Min, Hyun Jin Kim, Woon-Tae Jung, Ok-Jae Lee, Chang Yoon Ha, Sun Young Yi
Ewha Med J 2013;36(1):62-66.   Published online March 25, 2013
DOI: https://doi.org/10.12771/emj.2013.36.1.62

Transcatheter arterial chemoembolization (TACE) has become an effective alternative treatment strategy for patients with inoperable hepatocellular carcinoma (HCC). Although TACE is relatively safe, acute respiratory distress syndrome associated with pulmonary lipiodol embolism is a rare and potentially fatal complication. We report a rare case of acute respiratory distress syndrome after TACE for inoperable HCC. A 75-year-old man, with huge HCC in right lobe, was treated by TACE for the first time. Seven hours after uneventful TACE procedure, he felt dyspneic and his oxygen saturation recorded by pulse oximetry (SpO2) fell to 80% despite of applying non-rebreathing mask. He underwent mechanical ventilation with a protective ventilatory strategy. We experienced a case of acute respiratory distress syndrome after TACE for HCC.

  • 483 View
  • 1 Download
[English]
Angiogenic Inhibitor Induced Complicated Reflux Esophagitis
Jae-In Ryu, Hye-Kyung Jung, Min-Sun Cho, Min-Jin Lee, Myung-Eun Song, Da-Yeon Oh, Ha Eung Song
Ewha Med J 2013;36(1):58-61.   Published online March 25, 2013
DOI: https://doi.org/10.12771/emj.2013.36.1.58

Sunitinib an inhibitor of the vascular endothelial growth factor receptor, is highly effective against renal cell carcinoma and is now widely used in patients with metastatic disease. Gastroesophageal reflux disease (GERD) is rarely reported as a side effect of sunitinib. We report two cases of GERD with upper gastrointestinal bleeding related to sunitinib administration. Both cases responded well to conservative management. Microscopic findings in both cases showed cellular atypia such as hyperchromasia, increases in nuclear size, and multinucleation. The cellular atypia of the squamous mucosa appears to be associated with reparative processes.

Citations

Citations to this article as recorded by  
  • Sunitinib

    Reactions Weekly.2013; 1456(1): 34.     CrossRef
  • 611 View
  • 0 Download
  • 1 Crossref
[English]
A Case of Early Adenocarcinoma at Esophagogastric Junction Treated with Cap-pitted Endoscopic Mucosal Resection
Ye Ri So, Dae Ho Kim, Hyun A Yun, Hwa Young Seok, Seong Hun Hong, Sang Wan Jung, Jae Myung Cha, Joung Il Lee, Kwang Ro Joo, Hyun Phil Shin, Jae Jun Park, Jung Won Jeoun
Ewha Med J 2012;35(2):124-128.   Published online September 30, 2012
DOI: https://doi.org/10.12771/emj.2012.35.2.124

Surgery is the primary treatment for adenocarcinoma originating from the esophagogastric junction. However, many physicians attempt various endoscopic treatments for the cases of early adenocarcinoma and high-grade dysplasia of esophagogastric junction in order to avoid the high risk of complications associated with surgical resection. Recently, there is an increasing tendency to use endoscopic mucosal resection for the management of early esophageal cancer due to low morbidity and mortality rates. We report here on a case of early adenocarcinoma at esophagogastric junction successfully treated with endoscopic mucosal resection.

  • 428 View
  • 1 Download
[English]
A Case of Lipiodol Pneumonitis After Transarterial Chemoembolization for Hepatocellular Carcinoma
So-I Kim, Yoo-Ri Kim, Hyun-Mi Heo, Suh-Eun Bae, Myung-Won Lee, Yun-Jung Choi, Go-Heun Kim, Tae-Hun Kim, Kwon Yoo, Il-Hwan Moon
Ihwa Ŭidae chi 2009;32(2):85-89.   Published online September 30, 2009
DOI: https://doi.org/10.12771/emj.2009.32.2.85

Hepatocellular carcinoma(HCC)is one of common causes of cancer-related death in Korea where the majority of HCC patients were Hepaitc B virus(HBV)carriers and have cirrhosis. Transarterial chemoembolization(TACE)is commonly applied to the treatment of multinodular HCC in Korea and careful selection of candidate is important for the risk of various side effects. Besides common side effects as fever, nausea, abdominal pain and elevation of liver enzyme, TACE may predispose to hepatic failure, ischemic cholecystitis, pulmonary embolism, cerebral embolism and pneumonitis. In previous studies, some cases of pulmonary and cerebral embolism cases were reported but lipiodol pneumonitis after TACE was rarely reported. A 65-year-old woman with a multinodular HCC associated with HBV infection, was treated with TACE. Seven days after the procedure, nonspecific respiratory symptoms such as dyspnea and dry cough developed. Chest X-ray and chest computed tomography showed diffuse ground glass opacities in whole lung fields, suggestive of lipiodol pneumonitis. After several days of supportive care with steroid administration, radiologic abnormalities and subjective symptoms were much improved, considered that the disease was compatible with lipiodol pneumonitis.

Citations

Citations to this article as recorded by  
  • Lipiodol Pneumonitis Following Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
    Sungkeun Kim, Hee Yeon Kim, Su Lim Lee, Young Mi Ku, Yoo Dong Won, Chang Wook Kim
    Journal of Liver Cancer.2020; 20(1): 60.     CrossRef
  • 500 View
  • 1 Download
  • 1 Crossref
[English]
The Mixed Hepatocellular-Cholangiocarcinoma Confirmed by Liver and Neck Node Biopsy
Hye Won Kang, Jae Jung Park, Il Hwan Moon, Seo Woo Kim, Hyun Kyung Kim, Hyun Jung Oh, Go Heun Kim, Yoon Jung Choi, Hyun Mi Huh, Young Wook Roh, Tae Hun Kim, Kwon Yoo, Ji Yoon Bae, Dong Eun Song
Ihwa Ŭidae chi 2009;32(2):79-84.   Published online September 30, 2009
DOI: https://doi.org/10.12771/emj.2009.32.2.79

Mixed hepatocellular-cholangiocarcinoma accounts for about 1% of all hepatocellular carcinoma. In many cases, mixed hepatocellular-cholangiocarcinoma has been misdiagnosed as hepatocellular carcinoma or cholangiocarcinoma because of the indistinctive clinical course and radiologic findings. The clinical course and the pathologic characters are not known well, but it resembles the characteristics of hepatocellularcarcinoma rather than cholangiocarcinoma. So mixed hepatocellular-cholangiocarcinoma was classified as a kind of hepatocellular carcinoma. But the growth and dissemination rate is faster than that of hepatocellular carcinoma and the prognosis more poor. So the exact diagnosis is important. Authors experienced a patient who has the mixed hepatocellular-cholangiocarcinoma diagnosed by liver and neck node biopsy in patient who complain-ed abdominal discomfort and palpable mass, so we report the case.

Citations

Citations to this article as recorded by  
  • A Case of Curative Resection of Advanced Combined Hepatocellular-cholangiocarcinoma after Neoadjuvant Chemotherapy
    Jee Eun Choi, Kyung Hee Kim, Seon A Kim, Jung Hwan Lee, Sang Myung Woo, Sang-Jae Park, Eun Kyung Hong, Woo Jin Lee
    Korean Journal of Pancreas and Biliary Tract.2016; 21(2): 101.     CrossRef
  • 489 View
  • 0 Download
  • 1 Crossref
[English]
Primary Cutaneous Mucinous Carcinoma of the Lower Eyelid
Seung Eun Hong, So Ra Kang
Ihwa Ŭidae chi 2008;31(1):45-48.   Published online June 30, 2008
DOI: https://doi.org/10.12771/emj.2008.31.1.45
Background

Primary cutaneous mucinous carcinoma of the eyelid is an adenocarcinoma of the eccrine glands. These tumor is a rare ocular adnexal neoplasm that has a predilection for the periorbital and scalp region. It is more common in men and occur primarily in 50-70 year-old age range. We present the occurrence, clinical and histological features, and management of this tumour in a old male, who could exclude the presence of primary mucinous carcinoma elsewhere by extensive systemic evaluation.

Methods

A 67-year-old male presented with a small nodular erythematous nontender left lower lid lesion, which had increased in size and pigmentation over four years. Pneumoconiosis was noted on preoperative chest CT, but it was correlated with his occupational history. Lymphatic involvement was not noted on physical examination. So he underwent wide local excision with frozen section control of the margins. Clear margin were achieved and the defect was repaired with a local rotation flap.

Results

Histologic examination showed mucinous carcinoma of the eccrine glands. A whole body screening test(PET) was performed to excluded the presence of primary mucinous carcinoma elsewhere metastating to the eyelid, or any distant spread from the eyelid lesion. PET demonstrated mildly increased hypermetabolism in both lungs and hypermetabolic lymph nodes at both supraclavicular areas and mediastinum. But extensive systemic workup, including abdominal ultrasonography, upper and lower gastrointestinal endoscope, neck CT, and lung biopsyrevealed no other abnormal lesion. Immunohistochemical markers including CEA, S-100, CK-PAN, CK7, CK-20, TTF-l were also helpful in establishing the diagnosis of the primary cutaneous mucinous carcinoma of the skin. There has been no recurrence of tumor 2 months following excision.

  • 365 View
  • 0 Download
[English]
A Case of Hepatoid Adenocarcinoma without Involving Liver Parenchyme
Yoon Hee Jun, Tae Hun Kim, Kum Hei Ryu, So Yeon Lim, Ju Ho Lee, Shi Nae Lee
Ihwa Ŭidae chi 2007;30(1):61-66.   Published online March 30, 2007
DOI: https://doi.org/10.12771/emj.2007.30.1.61

Hepatoid adenocarcinoma was described by Ishikura in 1985 for the first time. It is a very rare variant of adenocarcinoma characterized by morphological and functional features of hepatocyte differentiation. It is most commonly presented as gastric adenocarcinoma with otherwise unexplained elevation of serum alpha-fetoprotein level. Most of the patients with gastric hepatoid adenocarcinoma were diagnosed in advanced stages having vascular invasion and/or extensive metastasis in liver or lymph nodes. Accordingly, the prognosis of hepatoid adenocarcinoma is dismal. We experienced a typical case of gastric hepatoid adenocarcinoma and described the clinical features.

  • 253 View
  • 0 Download

Original Articles

[English]
The Role of Helicobacter Pylori in Pancreatico-Biliary Disease
Sun Young Yi
Ihwa Ŭidae chi 2006;29(1):17-21.   Published online March 30, 2006
DOI: https://doi.org/10.12771/emj.2006.29.1.17
Objectives

The role of Helicobacter pylori(HP) in benign and malignant pancreatico-biliary tract disease is concerned in recent papers. The urease gene of Hp were found in human bile, and bacteria morphologically resembling Hp were found in resected gallbladder mucosa from patients with gallbladder disease. It was hypothesized that there is an association between the presence of Hp in bile and pancreatico-biliary disease. The aims of this study are to examine if Hp exist in the bile juice and to investigate whether Hp plays a role in the pancreatico-biliary disease.

Methods

Thirty-eight patients (18 males and 20 females, mean age 71 ?27yr ; range 45-92yr) with gallstone and malignant pancreatico-biliary disease were enrolled in this study ; 23 cases were gallstone diseases, 10 cases were cholangiocarcinomas, and 5 cases were pancreatic cancers. Thirty-eight controls were age- and sex-matched and enrolled from subject attending routine medical check-up. The presence of Hp in stomach was confirmed by ?4C-breath test. The polymerase chain reaction (PCR) assay was used to detect the Hp in bile.

Results

The Hp-positive rate in stomach was much higher in control (26/38,68.4%) than the patients with pancreatico-biliary disease(l1/38, 28.9%) (p<0.01). The Hp-positive rate in bile of pancreatico-biliary disease was 18.4% but, there is no relation between of the presence of Hp in the stomach and in the bile (p=0.33). Also there was no significant difference of the presence of Hp in bile (p>0.05) and stomach (p=0.28) between benign and malignant disease.

Conclusion

The Hp-positive rate in bile was similar in benign and malignant pancreatico-biliary disease. But Hp may not be important risk factor in pancreatico-biliary disease in Hp-prevatent country like south Korea.

  • 283 View
  • 0 Download
[English]
Renal Cell Carcinoma Associated with Paraneoplastic Symdrome Mimicking Pyelonephritis
Min Cheol Han, Jae Hun Kim, Sung Jae Park, Dong Won Byun, Duk Hee Kang, Bong Suk Shim
Ihwa Ŭidae chi 2004;27(2):83-86.   Published online September 30, 2004
DOI: https://doi.org/10.12771/emj.2004.27.2.83

Renal cell carcinoma can presents wide range of signs and symptoms, and commonly associated with paraneoplastic syndrome. Paraneoplastic manifestations are present in up to 20% of patients with renal cell carcinoma. There is convincing evidence that renal cell carcinoma tumor cells elaborate proteins that serve as mediators of endocrine (ex ; ectopic production of parathyroid hormone-related protein or erythropoietin) as well as nonendocrine paraneoplastic syndromes. A paraneoplastic syndrome may be the various clinical presentation of renal cell carcinoma in a significant number of patients, therefore mimicked other general disease. We report a case of renal cell carcinoma associated with paraneoplastic syndrome mimicking pyelonephritis.

  • 329 View
  • 0 Download

Case Report

[English]
A Case of Mucinous Cystic Adenocarcinoma of the Pancreas
Hyun-Ju Song, Doe-Young Kim, Hye-Kyoung Jung, Seung-Hyun Nam, Il-Hwan Moon, Hea-Soo Koo
Ihwa Ŭidae chi 2002;25(2):97-103.   Published online September 30, 2002
DOI: https://doi.org/10.12771/emj.2002.25.2.97

Nowadays increasing use of abdominal ultrasound in routine check-up may increase the detection rate asymtomatic cystic lesions of pancreas. Even through the majority of the cystic lesions of pancreas is pseudocyst, about 10-15% of those lesions are caused by pancreatic cystic tumor. In the pancreatic cystic tumor, especially, mucinous cystic tumor should be exicised due to its malignant potential, while the pancreatic pseudocyst or serous cystic tumon can be observed for a period or treated medically. Several clinical, radiological, biochemical and pathologic guidelines have been developed in order to distinguish among them. Among pancreatic cystic tumors, mucinous cystic adenocarcinoma is very rare and accounts for only 1% of all pancreatic neoplasms. Unlike extremely poor prognosis of pancreatic adenocarcinoma, mucinous cystic adenocarcinoma has an indolent course and shows a good prognosis after its curative resection. Recently we experienced a 69-year-old woman who had a mucinous cystic adenocarcinoma of the pancreas. We report this case with a review of literature.

  • 300 View
  • 0 Download
Original Articles
[English]
Objective

To establish new in vitro model systems that better reflect in vivo condition, multicellular tumor spheroids(MTS) and raft culture were developed using cell lines of squamous cell carcinoma(SCCHN) of the head and neck in these 3-dimensional systems.

Materials and Methods

Four SCCHN cell lines were used for MTS and raft culture.

Results

All cell lines formed MTS, but only Tu-138 showed a good stratification at the airliquid interface in the raft culture system.

Conclusions

MTS and raft culture system were established successfully from the SCCHN cell lines.

  • 289 View
  • 0 Download
[English]
Diagnostic Value of Enhanced MRI with Gd-DTPA in the T Staging of Colorectal Carcinoma
Sun Wha Lee, Byung Chul Kang, Jung Soo Suh, Eung Bum Park, Kang Sup Shim
Ihwa Ŭidae chi 1999;22(1):49-54.   Published online March 30, 1999
DOI: https://doi.org/10.12771/emj.1999.22.1.49
Purpose

We studied to determine the usefulness of dynamic magnetic resonance imaging(MRI) in the preoperative evaluation of invasion of colorectal cancer and to compare its usefulness with the conventional CT. To observe the enhancement pattern of colorectal wall after iv administration of Gd-DTPA between normal and cancerous wall.

Materials & Methods

Twenty patients with colon cancer and 8 patients with rectosigmoid cancer, who were diagnosed between October 1997 and June 1998 by barium enema, colonoscopic biopsy were evaluated. The patients population consisted of 16 men and 12 women, with ages ranging from 46 to 68 years(mean 61years). Preoperative staging was done by conventional CT and dynamic MRI. All MR images were performed with 1.5T superconducting magneting unit(Vision, Siemens, Erlangen, Germany). 2D-FLASH(Fast Low-Angle Shot) sequence was used for the dynamic and delayed images(TR/TE/NEX/FA=72.5-117.3/4.1/1/80°), and acquisition time of 13-15sec.

For the dynamic images, five MR images were obtained with a single breath hold. Precontrast images(axial, or sagittal or coronal) was obtained first, and then dynamic MR images were obtained at 30, 60, 90, 120sec after intravenous injection of 0.1mmol/kg Gd-DTPA. Ten to fifteen delayed images were also obtained with the interval of 4-5 minutes with a single breath hold. Preoperative staging of CT and MRI were decided with a consensus by two radiologists. Pathologic staging were done by TNM classification.

Results

The dynamic MR image-determined stage of colorectal cancer correlated with histopathologic findings in 2 of 3 pT2 tumor(67%), 19 of 21 pT3(90%), and 4 of 4 pT4 tumors(100%). MRI correctily diagnosed tumor deposits of involved lymph nodes in 16 patients, overall accuracy was 57%(16/28%). And the signal intensities after IV Gd-DTPA administration between the cancerous wall and normal wall ws not significantly different at the 30, 60, and 90 seconds MR images with the indifferent Student t-test(p>0.05).

Conclusion

Dynamic MRI has a role for the preoperative assesment of colorectal carcinoma.

  • 338 View
  • 2 Download
[English]
Histological Classification of Endoscopically Diagnosed Polypoid Lesion of Stomach
Ho Jung Kim, Sun Hee Sung, Hea Soo Koo, Woon Sup Han, Ok Kyong Kim
Ihwa Ŭidae chi 1998;21(3):195-201.   Published online September 30, 1998
DOI: https://doi.org/10.12771/emj.1998.21.3.195
Objectives

Gastric polyp is histologically very diverse and its classification is still unsettled. The purpose of the article is to classify the endoscopically diagnosed polypoid lesions and to evaluate their malignant potential.

Methods

A retrospective study was done on 142 cases of endoscopically diagnosed gastric polypoid lesions from September 1993 to May 1996. We investigated their clinical findings, histopathology, and nuclear gradings of PCNA by immunohistochemistry.

Results

1) The mean age is 57.9 and sex ratio os 0.8:1

2) The most prevalent location is antrum(57.7%).

3) Morphologically, Yamada type II is the most frequent(35.9%).

4) Histologically, lesions are classified as true polyps and reactive lesions. True polyps are subclassified as hyperplastic polyp(61.2%), adenomatous polyp(19.4%), mixed adenomatous and hyperplastic polyp(10.2%), fundic gland polyp(2.0%), and adenocarcinoma(7.1%). Reactive lesions are subclassified as chronic superficial gastritis(68.2%), mucosal hyperplasia(15.9%), edema of lamina propria(9.1%), xanthoma(4.5%), and ectopic pancreas(2.3%).

5) Atypical changes is accompanied in 12 cases(20%) of hyperplastic polyps.

6) Adenocarcinoma arising from adenomatous polyp is noted in 6 cases. In hyperplastic polyp one case is combined with adenocarcinoma.

7) Among the true polyps single lesions are 127 cases(89.4%), and multiple lesions, 15 cases(10.6%)

8) Immunohistochemical staining for proliferating cell nuclear antigen(PCNA) reveals that hyperplastic polyps show focal positive rection in the area of pit and fundus, and adenomatous polyps show diffuse positive reaction. Dysplastic foci in both adenomatous and hyperplastic polyps shows diffuse positive reaction of PCNA.

Conclusion

Endoscopically diagnosed polypoid lesions show variable histologic findings ranging from chronic superficial gastritis to adenocarcinoma. They are mainly subclassified as histologically true polyps and reactive lesions. Some of true polyps have atypical changes of varing dgree in not only adenomatous polyps but also hyperplastic polyps.

  • 437 View
  • 0 Download
[English]
AgNORs, PCNA, and DNA Ploidy in Enfometrial Hyperplasia and Endometrial Carcinoma
Sun Hee Sung
Ihwa Ŭidae chi 1998;21(1):47-53.   Published online March 31, 1998
DOI: https://doi.org/10.12771/emj.1998.21.1.47

Endometrial hyperplasia(EH) and endometrial carcinoma(EC) very in their biologic potential, which may be correlated with the histologic grade. Evaluation of cellular kinetics, which may prove to be another measure of predicting biologic behavior. Accessments of AgNORs and PCNA(proliferative cell nuclear antigen) indeces in 33 cases of EH including 16 cases of simple hyperplasia(SH), 8 of complex hyperplasia(CH), and 9 of atypical hyperplasia(AH), and 28 of EC including 7 of grade I, 12 of grade II, and 6 of grade III were performed. The results were as follows :I, 12 of grade II, and 6 of grade III were performed. The results were as follows : 1. AgNOR counts per glandular cells(Mean SD) were 2.7±0.2 in normal proliferative and 2.3±0.2 in secretory endometrium, and increased to 3.2±0.3 in SH, 3.5±0.3 in CH, to 5.4±0.4 in AH, and finally 6.9±0.5 in endometrioid carcinoma(grade I: 5.8±0.7, grade II: 6.7±0.6, grade III: 8.4±0.9). 2. PCNA indeces(percentages of nuclear positive cells of total cells of glands) were 16±14.2 in normal proliferative endometrium and 12±8.1 in secretory endometrium, and increased to 18.4±14.7 in SH, 21.6±17.8 in CH, 36.4±27.4 in AH, and finally 42.1±31.3 in EC(grade I: 38.3±23.2,grade II: 39.4±25.4, and grade III: 58.4±35.3). 3. DNA aneuploidy was detected in 4 cases of EC(40%), and tended to be more frequently found in poorer histologic grade. This data suggest that cell kinetic evaluation of EH and EC using AgNORs and PCNA is well correlated with histologic grade. And with the aspect of biologic potential, AH could be regarded as well differentiated EC.

  • 302 View
  • 0 Download
TOP